Ascelia Pharma (publ) is a Swedish limited liability company. The company’s governance is based on Swedish law, its Articles of Association and internal rules and instructions.
When cancer cells spread to distant lymph nodes, tissues or organs, it is called metastatic cancer, and the metastatic tumor is the same type of cancer as that of the primary tumor. Cancer can spread to any part of the body, but certain areas are more prone to metastases than others.
Gastric cancer is a disease in which cancer cells form in the lining of the stomach. In western countries, 80-90 percent of gastric cancer patients are diagnosed at an advanced stage or have disease relapse within five years.
Ascelia has established a development program for lead candidate Mangoral, consisting of a pivotal Phase III efficacy study and two supportive studies. The clinical development strategy for Oncoral, Ascelia´s second drug candidate, is to obtain Phase II data and then to partner for the further development.